Table 2.
Exosomes | OS7 models in vivo/in vitro | Measurement of OS | Bioactivate ingredients | Ref. |
---|---|---|---|---|
Huc-MSC-exos | IRI2/H2O2 | SOD1, MDA, ROS | MnSOD | [32] |
BM-MSC-exos | AβOs | ROS | Catalase | [31] |
CPCs-exos | Doxorubicin and trastuzumab | ROS | SOD, miR-146a-5p | [43] |
Exosomes from young cells | Young cell model | ROS | GSTM2 | [44] |
Huc-MSC-exos | CCl4/CCl4 or H2O2 | ROS, 8-OHdG, MDA | GPX1 | [40] |
BM-MSC-exos | H2O2 | ROS | Mitochondrial proteins | [42] |
Huc-MSC-exos | Seizure/H2O2 | CAT, SOD, GSH-Px, FRAP, TOM20, FIS1, COX IV, iNOS, HMGB1, HO-1, Nrf2, 8-OHdG,4-HNE, DT | miR-215-5p, miR-424-5p, miR-31-3P, miR-193b-3p, and miR-200b-3p | [10] |
Huc-MSC-exos | AMI | GSH, ROS, MDA | miR-23a-3p | [48] |
BM-MSC-exos | IS5 | ROS | miR-132-3p | [51] |
Hamsc-exos | POI/POI | ROS | miR-320a | [47] |
BM-MSC-exos | H2O2 | SOD, ROS, MDA | miR-214 | [49] |
ASC-exos | UVB | ROS | miR-10a-5p | [50] |
Exosomes from astrocyte | Oxygen and glucose deprivation | SOD, GSH-Px,CAT, MDA | miR-29a | [52] |
M1-exos | ROS | miR-155 | [60] | |
Exosomes from vascular adventitial fibroblasts of normal rats | Primary VSMCs derived from SHR | ROS, NOX activity, NOX2 | miR-155-5p | [46] |
Exosomes from CMs | ROS, MDA, SOD | circHIPK3 | [54] |
1SOD expression; 2ischemia-reperfusion injury; 3acute kidney injury; 4unilateral ureteral obstruction; 5ischemic stroke; 6traumatic acute lung injury; 7oxidative stress.